Cited by 11,215Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Open access

Connolly, Stuart J., Ezekowitz, Michael D., Yusuf, Salim, Eikelboom, John, Oldgren, Jonas, Parekh, Amit, Pogue, Janice, Reilly, Paul A., Themeles, Ellison, Varrone, Jeanne, Wang, Susan, Alings, Marco, Xavier, Denis, Zhu, Jun, Diaz, Rafael, Lewis, Basil S., Darius, Harald, Diener, Hans-Christoph, Joyner, Campbell D., Wallentin, Lars·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0905561

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism. RESULTS: Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). The rate of major bleeding was 3.36% per year in the warfarin group, as compared with 2.71% per year in the group receiving 110 mg of dabigatran (P=0.003) and 3.11% per year in the group receiving 150 mg of dabigatran (P=0.31). The rate of hemorrhagic stroke was 0.38% per year in the warfarin group, as compared with 0.12% per year with 110 mg of dabigatran (P<0.001) and 0.10% per year with 150 mg of dabigatran (P<0.001). The mortality rate was 4.13% per year in the warfarin group, as compared with 3.75% per year with 110 mg of dabigatran (P=0.13) and 3.64% per year with 150 mg of dabigatran (P=0.051). CONCLUSIONS: In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage. Dabigatran administered at a dose of 150 mg, as compared with warfarin, was associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage. (ClinicalTrials.gov number, NCT00262600.)

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa0905561

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,636
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,110
Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation
Hylek, E. M., Evans‐Molina, C., Shea, C., Henault, L. E., & Regan, S. (2007) · Circulation · doi:10.1161/circulationaha.106.653048 · Cited by 1,063
Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range
Connolly, S. J., Pogue, J., Eikelboom, J., Flaker, G., Commerford, P., Franzosi, M. G., Healey, J. S., & Yusuf, S. (2008) · Circulation · doi:10.1161/circulationaha.107.750000 · Cited by 870

Flagged first, then by citations

Show all 18 references

Sorted by citations

Items 701–800 of 1,022

Perioperative management of patients on direct oral anticoagulants
Dubois, V., Dincq, A.-S., Douxfils, J., Ickx, B., Samama, C. M., Dogné, J., Gourdin, M. J., Châtelain, B., Mullier, F., & Lessire, S. (2017) · Thrombosis Journal · doi:10.1186/s12959-017-0137-1 · Cited by 114
Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)
Gelosa, P., Castiglioni, L., Tenconi, M., Baldessin, L., Racagni, G., Corsini, A., & Bellosta, S. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.07.016 · Cited by 113
Edoxaban in Asian Patients With Atrial Fibrillation
Lee, S., Choi, E., Han, K., Jung, J., Oh, S., & Lip, G. Y. H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.05.066 · Cited by 112
Newer oral anticoagulants: A review of laboratory monitoring options and reversal agents in the hemorrhagic patient
Miyares, M. A., & Davis, K. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110725 · Cited by 113
Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilate
Lip, G. Y. H., Noack, H., Clemens, A., Plumb, J. M., & Roskell, N. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-10-0642 · Cited by 111
Atrial fibrillation, anticoagulation, fall risk, and outcomes in elderly patients
Sellers, M., & Newby, L. K. (2011) · American Heart Journal · doi:10.1016/j.ahj.2010.11.002 · Cited by 111
Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation
Baker, W. L., & Phung, O. J. (2012) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.112.966572 · Cited by 111
Dabigatran Effects on the International Normalized Ratio, Activated Partial Thromboplastin Time, Thrombin Time, and Fibrinogen: A Multicenter, In Vitro Study
Dager, W. E., Gosselin, R. C., Kitchen, S., & Dwyre, D. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r179 · Cited by 111
Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention
Andrade, J. G., Krahn, A. D., Skanes, A. C., Purdham, D. M., Ciaccia, A., & Connors, S. P. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.09.023 · Cited by 112
Patient Preferences for Oral Anticoagulation Therapy in Atrial Fibrillation: A Systematic Literature Review
Wilke, T., Bauer, S., Mueller, S., Kohlmann, T., & Bauersachs, R. M. (2016) · Patient · doi:10.1007/s40271-016-0185-9 · Cited by 115
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight
Hohnloser, S. H., Fudim, M., Alexander, J. H., WOJDYLA, D. M., Ezekowitz, J. A., Hanna, M., Atar, D., Hijazi, Z., Bahit, M. C., Al‐Khatib, S. M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037955 · Cited by 114
Trends in anticoagulant prescribing: a review of local policies in English primary care
Ho, K. H., van Hove, M., & Leng, G. C. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-5058-1 · Cited by 117
Dabigatran: how the drug company withheld important analyses
Cohen, D. (2014) · BMJ · doi:10.1136/bmj.g4670 · Cited by 110
Practical Management of Anticoagulation in Patients With Atrial Fibrillation
Kovacs, R. J., Flaker, G. C., Saxonhouse, S. J., Doherty, J. U., Birtcher, K. K., Cuker, A. C., Davidson, B. L., Giugliano, R. P., Granger, C. B., Jaffer, A. K., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.049 · Cited by 114
Shared Decision Making in Atrial Fibrillation
Seaburg, L., Hess, E. P., Coylewright, M. J., Ting, H. H., McLeod, C. J., & Montori, V. M. (2014) · Circulation · doi:10.1161/circulationaha.113.004498 · Cited by 109
Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial
Ng, K. H., Shestakovska, O., Connolly, S. J., Eikelboom, J. W., Avezum, Á., Díaz, R., Lanas, F. T., Yusuf, S., & Hart, R. G. (2015) · Age and Ageing · doi:10.1093/ageing/afv156 · Cited by 113
STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management
Tibi, P. R., McClure, R. S., Huang, J., Baker, R. A., Fitzgerald, D., Mazer, C. D., Stone, M. E., Chu, D., Stammers, A. H., Dickinson, T., et al. (2021) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2021.03.011 · Cited by 113
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial
Alcalai, R., Butnaru, A., Moravsky, G., Yagel, O., Rashad, R., Ibrahimli, M., Planer, D., Amir, O., Elbaz‐Greener, G., & Leibowitz, D. W. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab057 · Cited by 113
Evolving Treatments for Arterial and Venous Thrombosis
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 113
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
Cuker, A. C., & Husseinzadeh, H. D. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1185-7 · Cited by 111
Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation
Abdul‐Rahim, A. H., Moreno, A. C. P., Fulton, R. L., Jhund, P. S., Latini, R., Tognoni, G., Wikstrand, J., KJEKSHUS, J. K., Lip, G. Y. H., Maggioni, A. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013760 · Cited by 114
Periprocedural Management and Approach to Bleeding in Patients Taking Dabigatran
Weitz, J. I., Quinlan, D. J., & Eikelboom, J. W. (2012) · Circulation · doi:10.1161/circulationaha.112.123224 · Cited by 109
Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants
Hellwig, T. R., & Gulseth, M. P. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013504741 · Cited by 109
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion
Meier, B., Blaauw, Y., Khattab, A. A., Lewalter, T., Sievert, H., Tondo, C., & Glikson, M. (2015) · EuroIntervention · doi:10.4244/eijy14m09_18 · Cited by 110
Gender in atrial fibrillation: Ten years later
Michelena, H. I., Powell, B. D., Brady, P. A., Friedman, P. A., & Ezekowitz, M. D. (2010) · Gender Medicine · doi:10.1016/j.genm.2010.06.001 · Cited by 109
Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin‐activatable fibrinolysis inhibitor
Ammollo, C. T., Semeraro, F., Incampo, F., Semeraro, N., & Colucci, M. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03739.x · Cited by 109
Periprocedural Intracardiac Echocardiography for Left Atrial Appendage Closure
Berti, S. L., Paradossi, U., Meucci, F., Trianni, G., Tzikas, A., Rezzaghi, M., Stolkova, M., Palmieri, C., Mori, F., & Santoro, G. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.04.014 · Cited by 110
Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease
Sparkenbaugh, E., Chantrathammachart, P., Mickelson, J., van Ryn, J., Hebbel, R. P., Monroe, D. M., Mackman, N., Key, N. S., & Pawliński, R. (2014) · Blood · doi:10.1182/blood-2013-08-523936 · Cited by 108
Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation?
Rodriguez, R. A., Carrier, M., & Wells, P. S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12086 · Cited by 110
Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender
Shi, J., Wang, X., Nguyen, J., Bleske, B. E., Liang, Y., Liu, L., & Zhu, H. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.09.003 · Cited by 108
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Coronary Stenting
Faxon, D. P., Eikelboom, J. W., Berger, P. B., Holmes, D. R., Bhatt, D. L., Moliterno, D. J., Becker, R. C., & Angiolillo, D. J. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.965186 · Cited by 108
Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation
Landmesser, U., & Holmes, D. R. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr393 · Cited by 107
Edoxaban
Camm, A. J., & Bounameaux, H. (2011) · Drugs · doi:10.2165/11595540-000000000-00000 · Cited by 107
Trends in Oral Anticoagulant Choice for Acute Stroke Patients with Nonvalvular Atrial Fibrillation in Japan: The SAMURAI-NVAF Study
Toyoda, Ḱ., Arihiro, S., Todo, K., Yamagami, H., Kimura, K., Furui, E., Terasaki, T., Shiokawa, Y., Kamiyama, K., Takizawa, S., et al. (2015) · International Journal of Stroke · doi:10.1111/ijs.12452 · Cited by 108
Management of cardiovascular disease in patients with kidney disease
Kahn, M. R., Robbins, M. J., Kim, M. C., & Fuster, V. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.15 · Cited by 106
Comparisons between Novel Oral Anticoagulants and Vitamin K Antagonists in Patients with CKD
Harel, Z., Sholzberg, M., Shah, P. S., Pavenski, K., Harel, S., Wald, R., Bell, C. M., & Perl, J. M. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013040361 · Cited by 107
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial
Chao, T., Chen, S., Ruff, C. T., Hamershock, R. A., Mercuri, M. F., Antman, E. M., Braunwald, E., & Giugliano, R. P. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy807 · Cited by 106
Effect of hypertension duration and blood pressure level on ischaemic stroke risk in atrial fibrillation: nationwide data covering the entire Korean population
Kim, T., Yang, P., Yu, H. T., Jang, E., Shin, H. J., Kim, H. Y., Uhm, J., Kim, J., Sung, J., Pak, H., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy877 · Cited by 111
Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation
Seiffge, D. J., Paciaroni, M., Wilson, D., Koga, M., Macha, K., Cappellari, M., Schaedelin, S. A., Shakeshaft, C., Takagi, M., Tsivgoulis, G. K., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25489 · Cited by 108
“73m(2) using the CKD-EPI equation(34)); (5) patients treated with acute recanalization therapies for the index stroke (intravenous thrombolysis and/or endovascular”
BackgroundMethodResult
Direct Oral Anticoagulants
Levy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 108
Model-based Dose Selection for Phase III Rivaroxaban Study in Japanese Patients with Non-valvular Atrial Fibrillation
Tanigawa, T., Kaneko, M., Hashizume, K., Kajikawa, M., Ueda, H., Tajiri, M., Paolini, J. F., & Mueck, W. (2012) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-034 · Cited by 111
Thrombin generation and atherosclerosis
Kalz, J., Cate, H. T., & Spronk, H. M. H. (2013) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-013-1026-5 · Cited by 107
Anticoagulation in atrial fibrillation
Steinberg, B. A., & Piccini, J. P. (2014) · BMJ · doi:10.1136/bmj.g2116 · Cited by 104
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
Lip, G. Y. H., Pan, X., Kamble, S., Kawabata, H., Mardekian, J., Masseria, C., Bruno, A. S., & Phatak, H. M. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12863 · Cited by 106
The Assessment of the Watchman Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO) trial
Holmes, D. R., Reddy, V. Y., Buchbinder, M., Steín, K. M., Elletson, M., Bergmann, M., Schmidt, B., & Saw, J. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.03.007 · Cited by 109
National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018
Brieger, D. B., Amerena, J. V., Attia, J., Bajorek, B. V., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T. L., Haqqani, H. M., et al. (2018) · The Medical Journal of Australia · doi:10.5694/mja18.00646 · Cited by 110
Antithrombotic Therapy for Primary and Secondary Prevention of Ischemic Stroke
Greco, A., Occhipinti, G., Giacoppo, D., Agnello, F. G., Laudani, C., Spagnolo, M., Mauro, M. S., Rochira, C., Finocchiaro, S., Mazzone, P. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.07.025 · Cited by 115
How to define valvular atrial fibrillation?
Fauchier, L., Philippart, R., Clémenty, N., Bourguignon, T., Angoulvant, D., Ivanés, F., Babuty, D., & Bernard, A. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.06.002 · Cited by 108
Pharmacogenetics: past, present and future
Pirmohamed, M. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.08.006 · Cited by 105
Stroke Risk and Efficacy of Apixaban in Atrial Fibrillation Patients with Moderate Chronic Kidney Disease
Eikelboom, J. W., Connolly, S. J., Gao, P., Paolasso, E., Caterina, R. D., Husted, S., O'Donnell, M. J., Yusuf, S., & Hart, R. G. (2012) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2012.05.007 · Cited by 107
Survival Comparison of the Ross Procedure and Mechanical Valve Replacement With Optimal Self-Management Anticoagulation Therapy
Mokhles, M. M., Körtke, H., Stierle, U., Wagner, O., Charitos, E. I., Bogers, A. J. J. C., Gummert, J. F., Sievers, H., & Takkenberg, J. J. M. (2010) · Circulation · doi:10.1161/circulationaha.110.947341 · Cited by 105
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation
Steinberg, B. A., Holmes, D. N., Piccini, J. P., Ansell, J., Chang, P., Fonarow, G. C., Gersh, B. J., Mahaffey, K. W., Kowey, P. R., Ezekowitz, M. D., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000535 · Cited by 106
The Effects of Direct Thrombin Inhibition with Dabigatran on Plaque Formation and Endothelial Function in Apolipoprotein E-Deficient Mice
Lee, I.-O., Kratz, M. T., Schirmer, S. H., Baumhäkel, M., & Böhm, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.194837 · Cited by 106
Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack
Davis, S. M., & Donnan, G. A. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1107281 · Cited by 103
Cerebral Amyloid Angiopathy
DeSimone, C. V., Graff‐Radford, J., El‐Harasis, M. A., Rabinstein, A. A., Asirvatham, S. J., & Holmes, D. R. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.07.724 · Cited by 106
Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 105
Dabigatran-Induced Gastrointestinal Bleeding in an Elderly Patient with Moderate Renal Impairment
Wychowski, M. K., & Kouides, P. A. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q747 · Cited by 104
Management of Bleeding With Non–Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 109
Anticoagulant-Associated Intracranial Hemorrhage in the Era of Reversal Agents
Steiner, T., Weitz, J. I., & Veltkamp, R. C. (2017) · Stroke · doi:10.1161/strokeaha.116.013343 · Cited by 105
Direct Oral Anticoagulants Compared to Vitamin K Antagonist for the Management of Left Ventricular Thrombus
Iqbal, H., Straw, S., Craven, T. P., Stirling, K., Wheatcroft, S. B., & Witte, K. K. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12718 · Cited by 102
The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect
Merali, Z., Ross, S., & Paré, G. (2014) · Drug metabolism and drug interactions · doi:10.1515/dmdi-2014-0009 · Cited by 104
Patient outcomes using the European label for dabigatran
Clemens, A., Noack, H., Ferreira, J., Connolly, S. J., Yusuf, S., & Lip, G. Y. H. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-09-0734 · Cited by 104
Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?
Lip, G. Y. H., & Lane, D. A. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.01.031 · Cited by 103
The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism
Mavrakanas, T. A., & Bounameaux, H. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.12.007 · Cited by 104
Atrial high-rate episodes and stroke prevention
Camm, A. J., SIMANTIRAKIS, E. N., Goette, A., Lip, G. Y. H., Vardas, P. E., Calvert, M., CHLOUVERAKIS, G. I., Diener, H., & Kirchhof, P. F. (2016) · EP Europace · doi:10.1093/europace/euw279 · Cited by 104
Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients
Andreas, M., MOAYEDIFAR, R., Wieselthaler, G. M., Wolzt, M., Riebandt, J., Haberl, T., Angleitner, P., Schlöglhofer, T., Wiedemann, D., Schima, H., et al. (2017) · Circulation Heart Failure · doi:10.1161/circheartfailure.116.003709 · Cited by 103
Racial and ethnic differences in the prevalence, management, and outcomes in patients with atrial fibrillation: A systematic review
Ugowe, F. E., Jackson, L. R., & Thomas, K. L. (2018) · Heart Rhythm · doi:10.1016/j.hrthm.2018.05.019 · Cited by 102
Practice Variation in Anticoagulation Prescription and Outcomes After Device-Detected Atrial Fibrillation
Perino, A. C., Fan, J., Askari, M., Heidenreich, P. A., Keung, E. C., Raitt, M. H., Piccini, J. P., Ziegler, P., & Turakhia, M. P. (2019) · Circulation · doi:10.1161/circulationaha.118.038988 · Cited by 103
Antagonists of Vitamin K—Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives
Kasperkiewicz, K., Ponczek, M. B., Owczarek, J., Guga, P., & Budzisz, E. (2020) · Molecules · doi:10.3390/molecules25061465 · Cited by 107
2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline)
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2010) · Heart Rhythm · doi:10.1016/j.hrthm.2010.11.047 · Cited by 103
Anticoagulating obese patients in the modern era
Patel, J. P., Roberts, L. N., & Arya, R. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08826.x · Cited by 99
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation
Larsen, T. B., Rasmussen, L. H., Lip, G. Y. H., & Skjøth, F. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-02-0118 · Cited by 104
A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons
Brown, D. G., Wilkerson, E. C., & Love, W. E. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.10.027 · Cited by 102
Calidad de la anticoagulación con antagonistas de la vitamina K en España: prevalencia de mal control y factores asociados
Sánchez, M. A., Bertoméu, V., & Cequier, A. R. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2014.11.022 · Cited by 101
New oral anticoagulants in development
Weitz, J. (2009) · Thrombosis and Haemostasis · doi:10.1160/th09-07-0434 · Cited by 101
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled Trials
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 103
Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry
Mazurek, M., Huisman, M. V., Rothman, K. J., Paquette, M., Teutsch, C., Diener, H., Dubner, S., Halperin, J. L., Ma, C., Zint, K., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0555 · Cited by 105
The Role of Thrombin in Brain Injury After Hemorrhagic and Ischemic Stroke
Ye, F., Garton, H. J. L., Hua, Y., Keep, R. F., & Xi, G. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00855-4 · Cited by 103
“Dabigatran etexilate reduced endothelial permeability through inhibition of thrombin-induced cytoskeleton reorganization [177, 178], which may explain its favorable benefit-to-risk profile compared to warfarin for preventing ischemic stroke in patients with atrial fibrillation in a clinical trial (NCT00262600) [179] b…”
Background
Association Between Use of Pharmacokinetic‐Interacting Drugs and Effectiveness and Safety of Direct Acting Oral Anticoagulants: Nested Case‐Control Study
Gronich, N., Stein, N., & Muszkat, M. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2369 · Cited by 103
Novel oral anticoagulants in gastroenterology practice
Desai, J., Granger, C. B., Weitz, J. I., & Aisenberg, J. (2013) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.04.179 · Cited by 100
Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial
Rao, M. P., Halvorsen, S., WOJDYLA, D. M., Thomas, L. E., Alexander, J. H., Hylek, E. M., Hanna, M., Bahit, M. C., Lópes, R. D., Caterina, R. D., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002015 · Cited by 106
Risk of Stroke or Systemic Embolism in Atrial Fibrillation Patients Treated With Warfarin: A Systematic Review and Meta-analysis
Albertsen, I. E., Rasmussen, L. H., Overvad, T. F., Graungaard, T., Larsen, T. B., & Lip, G. Y. H. (2013) · Stroke · doi:10.1161/strokeaha.113.000883 · Cited by 101
Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP)
Friberg, L., Engdahl, J., Frykman, V., Svennberg, E., Levin, L.-Å., & Rosenqvist, M. (2013) · EP Europace · doi:10.1093/europace/eus217 · Cited by 100
The New Oral Anticoagulants in Clinical Practice
Gonsalves, W. I., Pruthi, R. K., & Patnaik, M. M. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.03.006 · Cited by 103
Extracorporeal Therapy for Dabigatran Removal in the Treatment of Acute Bleeding
Singh, T., Maw, T. T., Henry, B. L., Pastor‐Soler, N. M., Unruh, M. L., Hallows, K. R., & Nolin, T. D. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01570213 · Cited by 101
Anticoagulation‐related nephropathy
Wheeler, D., Giugliano, R. P., & Rangaswami, J. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13229 · Cited by 103
Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation
Hijazi, Z., Oldgren, J., Siegbahn, A. G., & Wallentin, L. C. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2016.255182 · Cited by 104
Society of Interventional Radiology Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions—Part I: Review of Anticoagulation Agents and Clinical Considerations
Davidson, J. C., Rahim, S., Hanks, S. E., Patel, I. J., Tam, A. L., Walker, T. G., Weinberg, I., Wilkins, L. R., & Sarode, R. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2019.04.016 · Cited by 103
Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
Paciaroni, M., Agnelli, G., Caso, V., Silvestrelli, G., Seiffge, D. J., Engelter, S. T., Marchis, G. M. D., Polymeris, A. A., Zedde, M., Yaghi, S. R., et al. (2019) · Stroke · doi:10.1161/strokeaha.119.025350 · Cited by 102
Hypercoagulable states: an algorithmic approach to laboratory testing and update on monitoring of direct oral anticoagulants
Nakashima, M. O., & Rogers, H. J. (2014) · Blood Research · doi:10.5045/br.2014.49.2.85 · Cited by 103
Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study
Bouillon, K., Bertrand, M., Maura, G., Blotière, P., Ricordeau, P., & Zureik, M. (2015) · The Lancet Haematology · doi:10.1016/s2352-3026(15)00027-7 · Cited by 110
D‐dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation – observations from the ARISTOTLE trial
Christersson, C., Wallentin, L. C., Andersson, U., Alexander, J. H., Ansell, J., Caterina, R. D., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., et al. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12638 · Cited by 103
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials
Yun, S., Vincelette, N. D., Acharya, U. H., & Abraham, I. L. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.09.010 · Cited by 100
Adherence to anticoagulant treatment with dabigatran in a real‐world setting
Schulman, S., Shortt, B., Robinson, M., & Eikelboom, J. W. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12241 · Cited by 99
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model
Grottke, O., van Ryn, J., Spronk, H. M. H., & Rossaint, R. (2014) · Critical Care · doi:10.1186/cc13717 · Cited by 99
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Caldeira, D., Barra, M., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7462-0 · Cited by 101
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature
Dufrost, V., Risse, J., Zuily, S., & Wahl, D. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0623-7 · Cited by 99
Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study
Stærk, L., Gerds, T. A., Lip, G. Y. H., Ozenne, B., Bonde, A. N., Lamberts, M., Fosbøl, E. L., Torp-Pedersen, C., Gislason, G., & Olesen, J. B. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12683 · Cited by 101
2021 Focused update of the 2017 consensus guidelines of the Asia Pacific Heart Rhythm Society (APHRS) on stroke prevention in atrial fibrillation
Chao, T., Joung, B., Takahashi, Y., Lim, T. W., Choi, E., Chan, Y., Guo, Y., Sriratanasathavorn, C., Oh, S., Okumura, K., et al. (2021) · Journal of Arrhythmia · doi:10.1002/joa3.12652 · Cited by 105
“The figure was redraw and modified from the paper by Lee et al 7 AF, atrial fibrillation; ED, emergency department; GI, gastrointestinal; ICH, intracranial hemorrhage; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant. hazard ratio [HR]: 0.39; 95% CI 0.22 to 0.67; p < 0.001).”
BackgroundInfluential
Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation
Flaker, G., Lópes, R. D., Hylek, E. M., WOJDYLA, D. M., Thomas, L. E., Al‐Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D. A., Hanna, M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.967 · Cited by 97

Authors: Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B. S., Darius, H., Diener, H.-C., Joyner, C. D., & Wallentin, L.
Affiliations: Population Health Research Institute (CA)
Lankenau Institute for Medical Research (US)
Uppsala University (SE)
Boehringer Ingelheim (United States) (US)
Werkgroep Cardiologische centra Nederland (NL)
St. John's National Academy of Health Sciences (IN)
Fu Wai Hospital (CN)
Carmel Medical Center (IL)
Vivantes Klinikum (DE)
Sunnybrook Health Science Centre (CA)
ORCID: Connolly, Stuart J.
Ezekowitz, Michael D.
Yusuf, Salim
Eikelboom, John
Oldgren, Jonas
Parekh, Amit
Alings, Marco
Xavier, Denis
Zhu, Jun
Lewis, Basil S.
Wallentin, Lars
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-09-17
Volume: 361
Issue: 12
Pages: 1139-1151
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0905561
OpenAlex: W2136489990
Cited by: 11,215
References: 18
Citations by year: 2026: 219 · 2025: 318 · 2024: 395 · 2023: 489 · 2022: 507 · 2021: 662 · 2020: 745 · 2019: 669 · 2018: 775 · 2017: 799 · 2016: 864 · 2015: 923 · 2014: 874 · 2013: 1000 · 2012: 915
FWCI: 419.63
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
PubMed (publishedVersion)
Pure Amsterdam UMC (publishedVersion)
Minerva Access (University of Melbourne) (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion)
Figshare (submittedVersion)
UnissResearch (Università degli Studi di Sassari) (submittedVersion)
Open Repository and Bibliography (University of Liège) (submittedVersion)
Funders: Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Sanofi
Daiichi-Sankyo
Eisai
Servier
Cilag
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: dabigatran, warfarin, atrial fibrillation, direct thrombin inhibitors, oral anticoagulants, stroke prevention, systemic embolism, major bleeding, hemorrhagic stroke, non-inferiority, mortality, fixed-dose dosing, bleeding risk stratification, anticoagulation
MeSH terms: Dabigatran, Aged, Anticoagulants, Atrial Fibrillation, Benzimidazoles, Double-Blind Method, Dyspepsia, Embolism, Female, Follow-Up Studies, Hemorrhage, Humans, Liver, Male, Middle Aged, Myocardial Infarction, Prodrugs, Pyridines, Warfarin, Chi-Square Distribution, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks